Estimation of quantitative genetic and stability parameters in maize under high and low N levels

AB It is important to breed maize (Zea mays L) cultivars with high performance under variable N levels. We studied the effect of N levels and estimated quantitative genetic parameters for grain yield, quality, and other traits, and examined stability of performance for grain yield in diverse Chinese maize germplasm. From 2006 to 2008, each year 20 and in total 30 maize hybrids, including commercial hybrids currently grown in this region and other ex¬perimental hybrids as well as high-oil hybrids, were tested using nine environments (location-year combinations) in North China Plain. In each environment, two replicated trials were grown: one under high N application rate (HN, 225 kg N ha-1) and the other under low N application rate (LN, no N fertilization). Compared to HN, grain yield was significantly reduced (35.6%) under LN level, as well as kernel number per ear, 1000-kernel weight, plant and ear heights, and protein concentration. In the analysis over environments under each N level, genotypic variance was significant and heritability was high for all traits. In the analyses across N levels and environments, genotypic variance was significant for all traits and larger than the genotype × N and/or environment interaction variance components except for protein concentration. In stability analyses across N levels, hybrids differed for their linear response to environments, and some showed dissimilar response under HN and LN levels. Our results indicated that breeding maize adapted to variable N levels is feasible with the Chinese germplasm available in the summer breeding programs in North China Plain. Multi-environment tests are required to identify hybrids with high grain yield under variable N conditions, and examining yield stability separately under HN and LN would be useful

Canagliflozin and renal outcomes in type 2 diabetes and nephropathy

BACKGROUND Type 2 diabetes mellitus is the leading cause of kidney failure worldwide, but few effective long-term treatments are available. In cardiovascular trials of inhibitors of sodium–glucose cotransporter 2 (SGLT2), exploratory results have suggested that such drugs may improve renal outcomes in patients with type 2 diabetes. METHODS In this double-blind, randomized trial, we assigned patients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral SGLT2 inhibitor, at a dose of 100 mg daily or placebo. All the patients had an estimated glomerular filtration rate (GFR) of 30 to <90 ml per minute per 1.73 m2 of body-surface area and albuminuria (ratio of albumin [mg] to creatinine [g], >300 to 5000) and were treated with renin–angiotensin system blockade. The primary outcome was a composite of end-stage kidney disease (dialysis, transplantation, or a sustained estimated GFR of <15 ml per minute per 1.73 m2), a doubling of the serum creatinine level, or death from renal or cardiovascular causes. Prespecified secondary outcomes were tested hierarchically. RESULTS The trial was stopped early after a planned interim analysis on the recommendation of the data and safety monitoring committee. At that time, 4401 patients had undergone randomization, with a median follow-up of 2.62 years. The relative risk of the primary outcome was 30% lower in the canagliflozin group than in the placebo group, with event rates of 43.2 and 61.2 per 1000 patient-years, respectively (hazard ratio, 0.70; 95% confidence interval [CI], 0.59 to 0.82; P=0.00001). The relative risk of the renal-specific composite of end-stage kidney disease, a doubling of the creatinine level, or death from renal causes was lower by 34% (hazard ratio, 0.66; 95% CI, 0.53 to 0.81; P<0.001), and the relative risk of end-stage kidney disease was lower by 32% (hazard ratio, 0.68; 95% CI, 0.54 to 0.86; P=0.002). The canagliflozin group also had a lower risk of cardiovascular death, myocardial infarction, or stroke (hazard ratio, 0.80; 95% CI, 0.67 to 0.95; P=0.01) and hospitalization for heart failure (hazard ratio, 0.61; 95% CI, 0.47 to 0.80; P<0.001). There were no significant differences in rates of amputation or fracture. CONCLUSIONS In patients with type 2 diabetes and kidney disease, the risk of kidney failure and cardiovascular events was lower in the canagliflozin group than in the placebo group at a median follow-up of 2.62 years